Purpose of review Multiple sclerosis (MS) is an immune-mediated disorder that affects the
central nervous system (CNS), often first affecting people in early adulthood. Although most …

Introduction: Multiple sclerosis (MS) is a chronic inflammatory condition of the central
nervous system with heterogeneous features. Primary progressive (PP) MS is a rare disease …

Although the understanding of secondary progressive multiple sclerosis (SPMS) is evolving,
early detection of relapse-independent progression remains difficult. This is further …

The focus of multiple sclerosis research has recently turned to the relatively rare and clearly
more challenging condition of primary progressive multiple sclerosis (PPMS). Many risk …

Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of
ocrelizumab, a new B-cell–targeted therapy for multiple sclerosis (MS). Data Sources: A …

Background Ocrelizumab was approved for the treatment of relapsing multiple sclerosis
(RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug …

PMS represents a significant challenge, as the pathogenesis of the disease is not well
understood, no validated outcome metrics have been established and clinical trial …

Background: Many patients with multiple sclerosis (MS) experience suboptimal disease
control despite the use of disease-modifying therapy (DMT). Objective: To assess the …

Open-label extension (OLE) studies help inform long-term safety and efficacy of disease-
modifying therapies in multiple sclerosis (MS). We report exploratory analyses from a phase …

Ocrelizumab is a recombinant humanized monoclonal antibody selectively targeting CD20-
expressing B cells. The effect of ocrelizumab on primary progressive multiple sclerosis …